Deferred Tax Assets, Valuation Allowance of UroGen Pharma Ltd. from 31 Dec 2014 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
UroGen Pharma Ltd. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2014 to 31 Dec 2025.
  • UroGen Pharma Ltd. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $198,448,000, a 18% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

UroGen Pharma Ltd. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $198,448,000 +$29,893,000 +18% 31 Dec 2025 10-K 02 Mar 2026 2025 FY
Q4 2024 $168,555,000 +$24,989,000 +17% 31 Dec 2024 10-K 02 Mar 2026 2025 FY
Q4 2023 $143,566,000 +$13,965,000 +11% 31 Dec 2023 10-K 02 Mar 2026 2025 FY
Q4 2022 $129,601,000 +$28,982,000 +29% 31 Dec 2022 10-K 10 Mar 2025 2024 FY
Q4 2021 $100,619,000 +$23,656,000 +31% 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q4 2020 $76,963,000 +$26,370,000 +52% 31 Dec 2020 10-K 24 Mar 2023 2022 FY
Q4 2019 $50,593,000 +$22,344,000 +79% 31 Dec 2019 10-K 21 Mar 2022 2021 FY
Q4 2018 $28,249,000 +$16,524,000 +141% 31 Dec 2018 10-K 18 Mar 2021 2020 FY
Q4 2017 $11,725,000 +$7,567,000 +182% 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q4 2016 $4,158,000 -$341,000 -7.6% 31 Dec 2016 10-K 02 Mar 2020 2019 FY
Q4 2015 $4,499,000 +$1,948,000 +76% 31 Dec 2015 10-K 28 Feb 2019 2018 FY
Q4 2014 $2,551,000 31 Dec 2014 20-F 15 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.